Tamoxifen inhibits particulate-associated protein kinase C activity, and sensitises cultured human glioblastoma cells not to etoposide but to γ- radiation and BCNU

European Journal of Cancer

Volumn 35, Issue 5, 1999, Pages 833-839

  Brondani Da Rocha, A ^a,b   Mans, D R A ^a,b   Bernard, E A ^b   Ruschel, C ^b   Logullo, A F ^c   Wetmore, L A ^d   Leyva, A ^d   Schwartsmann, G ^a,b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Brazil)

^d CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

Radiation; BCNU; Cell culture; Drug interaction; Etoposide; Glioblastoma; Protein kinase C; Tamoxifen

Indexed keywords

CARMUSTINE; ESTROGEN RECEPTOR; ETOPOSIDE; PROTEIN KINASE C; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSOL; CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GAMMA RADIATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; PARTICULATE MATTER; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CARMUSTINE; CELL DIVISION; DRUG SYNERGISM; ETOPOSIDE; GAMMA RAYS; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; PROTEIN KINASE C; RECEPTORS, ESTROGEN; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 0344654695     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00003-9     Document Type: Article

References (45)

1. Patchell RA. Chemotherapy of primary brain tumors. In: Perry MC, ed. The Chemotherapy Source Book. Baltimore, U.S.A., Williams & Wilkins, 1992, 908-917.
2. Levin VA, Gutin PH, Leibel S. Neoplasms of the central nervous system. In: DeVita Jr VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia, U.S.A., Lippincott Co, 1993, 1679-1737.
3. Powis G., Abraham R.T., Ashendel C.L., et al. Anticancer drugs and signaling targets: principles and examples. Int. J. Pharmacognosy. 33:(suppl.):1995;17-26.
4. Stabel S., Parker P.J. Protein kinase C. Pharmac. Ther. 51:1991;71-95.
5. Grant S., Jarvis W.D. Modulation of drug-induced apoptosis by interruption of the protein kinase C signal transduction pathway: a new therapeutic strategy. Clin. Cancer Res. 2:1996;1915-1920.
6. Couldwell W.T., Uhm J., Antel J.P., Yong V.W. Enhanced protein kinase C activity correlates with the growth rate of malignant human gliomas. Neurosurgery. 29:1991;880-887.
7. Couldwell W.T., Antel J.P., Yong V.W. Enhanced protein kinase C activity correlates with the growth rate of malignant gliomas: Part II. Effects of glioma mitogens and modulators of PKC. Neurosurgery. 31:1992;717-724.
8. Baltuch G.H., Yong V.W. Signal transduction for proliferation of glioma cells in vitro occurs predominantly through a protein kinase C-mediated pathway. Brain Res. 710:1996;143-149.
9. Furr B.J.A., Jordan V.C. The pharmacology and clinical uses of tamoxifen. Pharmac. Ther. 25:1984;127-205.
10. Markwalder T.M., Waelti E.R. Endocrine manipulation of meningiomas with medroxyprogesterone acetate. Dev. Oncol. 66:1991;267-273.
11. Koehorst S.G., Jacobs H.M., Thijssen J.H., Blankenstein M.A. Detection of an estrogen receptor-like protein in human meningiomas by band shift assay using a synthetic estrogen responsive element (ERE). Br. J. Cancer. 68:1993;290-294.
12. Zugmaier G., Lippman M.E. Effects of TGF β on normal and malignant mammary epithelium. Ann. N. Y. Acad. Sci. 593:1990;272-275.
13. Vertosik F.T., Selker R.G., Pollack I.F., Arena V. The treatment of intracranial malignant gliomas using orally administered tamoxifen therapy: preliminary results in a series of 'failed' patients. Neurosurgery. 30:1992;897-903.
14. Couldwell W.T., Hinton D.R., Surnock A.A., et al. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin. Cancer Res. 2:1996;619-622.
15. Pollack I.F., Darosso R.C., Robertson P.L., et al. A phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood. Clin. Cancer Res. 3:1997;1109-1115.
16. Pollack I.F., Randall M.S., Kristofik M.P., Kelly R.H., Selker R.G., Vertosik F.T. Effect of tamoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitro. Cancer Res. 50:1990;7134-7138.
17. Baltuch G., Couldwell W.T., Villemure J.G., Yong V.W. Protein kinase C inhibitors suppress cell growth in established and low passage glioma cell lines. A comparison between staurosporine and tamoxifen. Neurosurgery. 33:1993;495-501.
18. Monks A., Scudiero D., Skehan P., et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. 83:1991;757-766.
19. Chou T-C, Talahay P. Quantitative analysis of dose-effect relationship: the combined effects of multiple drugs on enzyme inhibitors. In: Weber G, ed. Advances in Enzyme Regulation. New York, U.S.A., Pergamon Press, 1983, 27-55.
20. Chou T-C. The median effects principle and the combination index for quantitation of synergism and antagonism. In: Chou T-C, Rideout DC, eds. Synergism and Antagonism in Chemotherapy. San Diego, U.S.A., Academic Press, 1991, 61-102.
21. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
22. Van Zoelen EJJ, Delaey B, Van Der Burg G, Huylebroeck D. Detection of polypeptide growth factors: application of specific bio-assays and PCR technology. In: McKay I, Leigh I, eds. Growth Factors. A Practical Approach. New York, U.S.A., Oxford University Press, 1993, 12-34.
23. Swain AM, Lippman ME. Endocrine therapies of cancer. In: Chabner BA, Collins JM, eds. Cancer Chemotherapy: Principles and Practice. Philadelphia, U.S.A., Lippincott Co, 1990, 59-109.
24. Jean-Claude B.J., Vasilescu D., Damian Z., Mustafa A., Langleben A., Leyland-Jones B. Modulation of BCNU resistance in an AGT-proficient glioma cell line by tamoxifen. Proc. Am. Soc. Clin. Oncol. 15:1996;A392.
25. Gundimeda U., Chen Z-H., Gopalakrishna R. Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells. J. Biol. Chem. 271:1996;13504-13524.
26. Lavie Y., Jones R.C., Cao H.T., et al. Tamoxifen induces selective membrane association of protein kinase C epsilon in MCF-7 cells. Proc. Am. Assoc. Cancer. Res. 37:1996;A2890.
27. Cabot M.C., Zhang Z., Cao H., et al. Tamoxifen activates cellular phospholipase C and D and elicits protein kinase C translocation. Int. J. Cancer. 70:1997;567-574.
28. Couldwell W.T., Hinton D.R., He S., et al. Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines. FEBS Lett. 345:1994;43-46.
29. Zhang W., Lawa R.E., Hintona D.R., Su Y., Couldwell W.T. Growth inhibition and apoptosis in human neuroblastoma SK-N-SH cells induced by hypericin, a potent inhibitor of protein kinase C. Cancer Lett. 96:1995;31-35.
30. Zhang W., Hara A., Sakai N., Andoh T., Yamada H., Nozawa Y. Radiosensitization and inhibition of deoxyribonucleic acid repair in rat glioma cells by long-term treatment with 12-O-tetradecanoylphorbol 13-acetate. Neurosurgery. 32:1993;432-437.
31. Takuwa N., Zhou W., Kumada M., Takuwa Y. Activators of protein kinase C induce p34cdc2 histone H1 kinase stimulation in Swiss 3T3 fibroblasts. Biochem. Biophys. Res. Commun. 188:1992;1084-1089.
32. Kosaka C., Sasaguri T., Ishida A., Ogata J. Cell cycle arrest in the G2 phase induced by phorbol ester and diacylglycerol in vascular endothelial cells. Am. J. Physiol. 270:1996;C170-C178.
33. Fuks Z, Weichselbaum RR. Radiation therapy. In Mendelsohn J, Howley PM, Israel MA, Liotta LA, eds. The Molecular Basis of Cancer. Philadelphia, U.S.A., WB Saunders, 1995, 401-431.
34. Zhang W., Yamada H., Sakai N., Niikawa S., Nozawa Y. Enhancement of radiosensitivity by tamoxifen in C6 glioma cells. Neurosurgery. 31:1992;725-729.
35. Zhang W., Hinton D.R., Surnock A.A., Couldwell W.T. Malignant glioma sensitivity to radiotherapy, high-dose tamoxifen, and hypericin: corroborating clinical response in vitro: case report. Neurosurgery. 38:1996;587-591.
36. Acevedo-Duncan M., Gump J., Zhang R., Wagner H., Greenberg H. Interaction of radiation with glioma protein kinase C and cell cycle. Proc. Am. Assoc. Cancer Res. 35:1994;A3669.
37. Acevedo-Duncan M., Sosa M., Gump J., et al. Effects of radiation on growth, protein kinase C and cell cycle of human glioma xenografts. Proc. Am. Assoc. Cancer Res. 36:1995;A3593.
38. Tew K, Colvin OM, Chabner BA. Alkylating agents. In: Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy: Principles and Practice, 2nd edition. Philadelphia, U.S.A., Lippincott-Raven, 1996, 297-332.
39. Jean-Claude B.J., Vasilescu D., Damian Z., Mustafa A., Langleben A., Leyland-Jones B. Modulation of BCNU resistance in an AGT-proficient glioma cell line by tamoxifen. Proc. Am. Soc. Clin. Oncol. 15:1996;A392.
40. Lock R.B., Thompson B.S., Stribinskiene L. Activation of p34cdc2 and p34cdc2 kinases in association with potentiation of etoposide-induced apoptosis in HeLa cells. Proc. Am. Assoc. Cancer Res. 37:1996;A154.
41. Stuart N.S.A., Philip P., Harris A.L., et al. High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in P-glycoprotein expressing cell lines. Br. J. Cancer. 66:1992;833-839.
42. Prommier Y.G., Fesen M.R., Goldwasser F. Topoisomerase II inhibitors: the epipodophyllotoxins, m-AMSA, and the ellipticine derivatives (Chapter 18). In: Chabner B.A., Longo D.L., eds. Cancer Chemotheraphy and Biotheraphy: Principles and Practice, 2nd edition. Philadelphia, U.S.A., Lippincott-Raven, 1996, 435-462.
43. Fry A.M., Harris A.L., Hickson I.D. Phosphorylation of human topoisomerase II. Br. J. Cancer. 65:(Suppl. 16):1992;24.
44. Langleben A., Preul M., Tampieri D., et al. Combined hormonal and chemotherapy treatment of recurrent high grade astrocytoma. Proc. Am. Assoc. Cancer Res. 35:1994;A1348.
45. Murakami MS, Strobel MC, VandeWoude GF. Cell cycle regulation, oncogenes, and antineoplastic drugs. In: Mendelsohn J, Howley PM, Israel MA, Liotta LA, eds. The Molecular Basis of Cancer. Philadelphia, U.S.A., WB Saunders, 1995, 3-17.